HEMOSTEMIX

Safe and Efficacious Autologous Cellular Medicine for CLI, PAD, Angina, Ischemic and Dilated Cardiomyopathy

用于严重肢体缺血(CLI)、外周血管疾病(PAD)、心绞痛、缺血性和扩张性心肌病的安全和有效的自体细胞药物

MAY 26, 2021 / 2021年5月26日

FORWARD-LOOKING INFORMATION 前瞻性信息

This presentation contains forward looking statements that reflect management's expectations regarding the future growth and results of operational performance including but not limited to the scientific, financial, competitive and business prospects of Hemostemix Inc. ("Hemostemix" or the "Company"). This Presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information is generally, but not always identified by words such as "may", "would", "could", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "potential", "might", "seek", "budget", "outlook", and other similar expressions. In addition, forward looking statements include, but are not limited to, the Company's assessment of and targets for the stem-cell industry, including the potential opportunities and challenges in the current stem cell industry; matters pertaining to Hemostemix, including its strategy and anticipated and potential transactions and the characteristics thereof; future acquisition opportunities, partnerships, licensing opportunities and joint ventures and its pro forma impact to capitalization following the completion of any of the Company's business opportunities; matters pertaining to the Company's future research and development initiatives including future clinical trials, management's estimated timelines regarding the Company's clinical trials, regulatory approvals for ACP-01 and NCP-01, and many other projected timelines including regulatory approvals of the Company's submission(s); financial modeling matters, including metrics pertaining to anticipated financial and operational performance of operations; and, any matters pertaining to the potential for commercialization of its technology, sources and extent of necessary funding, manufacturing scalability and future business outcomes.

Actual results, performance and achievement(s) could differ materially from that expressed in, or implied by, any forward-looking information in this Presentation and, accordingly, investors should not place undue reliance on any such forward-looking information. Forward-looking information should not be read as guarantees of future performance or results. Forward-looking information and results could differ materially from general business, economic, competitive and regulatory risks now and in the future, including that the Company's current phase 2 clinical trial will be completed within the timelines and on the terms currently anticipated. As well, results may be inconsistent with general assumptions about the economic environment and stem cell industry environment, the business operations of Hemostemix including that each business will continue to operate in a manner consistent with past practice and pursuant to certain industry expectations and current market conditions.

Any forward-looking statements speak only as of the date on which such statement is made and the Company disclaims any intention or obligation to update or revise any forward-looking information as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to time and it is not possible for management to predict how such factors impact the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking information contained in this Presentation is based on the Company's current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to be correct. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this Presentation is intended to be nor may be construed to be an investment recommendation or a profit forecast.

HEMOSTEMIX – AT A GLANCE 公司概览

Global IP Portfolio
全球知识产权组合

91 Patents issued Worldwide 全球91项专利

5 patent families including automation of production patent / 5个专利系列，包括生产自动化专利

Expandable Technology Platform
可扩展的技术平台

ACP-01 – 5 indications / ACP-01 - 5个适应症

NCP-01 - stroke model as an indication / NCP-01--中风模型为适应症

Machine engineered 机器设计

Actionable Business Plan
可行的商业计划

Lean structure 精简的结构

Experienced board and management team 经验丰富的董事会和管理团队

Proven Scientific Advisory Board 成熟的科学顾问委员会

International Advisory Board 国际咨询委员会

Key Strategic Partnerships
主要战略合作关系

Licenses 许可证

By Indication by Country 按适应症和国家分类

Data Driven Biotech Company
数据驱动的生物技术公司

Historical Data >500 patients treated 历史数据 >500名患者得到治疗

12 Years of treatment History / 12年的治疗历史

Multiple Trials (2) and Investigator led studies (3) completed 完成多项试验（2）和研究者主导的研究（3）

Clinical Trials / Clinical Data
临床试验/临床数据

17 NA Sites : 65th patient enrollment / 17个北美站点: 第65位患者入组

Abstract results show 83% of patients (10 of 12) show improvement 摘要结果显示，83%的患者（12人中的10人）表现出改善

Endpoints reached Results expected in Q2 2021 达到终点 预计2021年第二季度出结果

BUILDING THE LEADING
STEM CELL COMPANY 建立领先的干细胞公司

Innovative cellular medicines have the potential to change the way we treat serious diseases and the practice of medicine for good. 创新的细胞药物有可能彻底改变我们治疗严重疾病的方式和医学实践。

HEMOSTEMIX Inc is developing safe and efficacious autologous cellular medicines to treat diseases of high unmet need, like CLI, PAD, Angina, Ischemic & Dilated Cardiomyopathy. HEMOSTEMIX公司正在开发安全有效的自体细胞药物，以治疗高度未满足需求的疾病，如CLI、PAD、心绞痛、缺血性和扩张性心肌病。

ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. / ACP-01已被用于治疗500多名患者，是一项随机、安慰剂对照、双盲试验的对象，该试验是针对已用尽所有其他方法挽救肢体不被截肢的晚期危重肢体缺血患者的安全性和有效性。

Hemostemix Clinical Pipeline: ACP-01, NCP-01, BCP-01 have the potential to treat many debilitating diseases with high unmet medical need. / Hemostemix临床管线：ACP-01、NCP-01、BCP-01有可能治疗许多具有高度未满足医疗需求的衰弱性疾病。

ACP-01 is a pioneering approach to the treatment of ischemia-based conditions of: / ACP-01是治疗以下缺血性疾病的开创性方法：

Critical Limb Ischemia (CLI) and Peripheral Arterial Disease (PAD) 严重肢体缺血（CLI）和外周动脉疾病（PAD）

Angina Dilated Cardiomyopathy, Ischemic Cardiomyopathy 心绞痛扩张型心肌病，缺血性心肌病

Future potential: Other Cardiovascular Diseases 未来潜力：其他心血管疾病

PATENTED AUTOLOGOUS
STEM CELL THERAPY PLATFORM TO DRIVE INNOVATION 获得专利的自体干细胞治疗平台，以推动创新

>500 Patients treated
超过500名患者得到治疗

Abstract results show improvement in 83% of patients tested[1] 摘要结果显示，83%的受测患者病情得到改善[1]

91 patents
91项专利

cover five patent families including automated production of autologous peripheral blood-based ACP-01 & NCP-01

涵盖五个专利系列，包括基于自体外周血的自动化生产

ACP-01 & NCP-01

Ongoing 17
正在进行的17项

Centre International Phase 2 Clinical Trial for Critical Limb Ischemia 针对严重肢体缺血的中心国际2期临床试验

ACP-01: Studied and clinically trialled for the treatment of ischemia-based conditions of:
ACP-01：用于治疗以下缺血性疾病的研究和临床试验

- Critical Limb Ischemia and Peripheral Arterial Disease 严重肢体缺血和外周动脉疾病
- Angina Dilated Cardiomyopathy 心绞痛扩张型心肌病
- Ischemic Cardiomyopathy 缺血性心肌病
- Future potential: Other Cardiovascular Diseases 未来潜力：其他心血管疾病

CLINICAL DEVELOPMENT
PIPELINE 临床开发管线

Candidate 候选药物	Indication 适应症	Preclinical 临床前	Phase I 第一期	Phase 2 第二期	Status 状况
ACP-01					
	Critical limb ischemia 严重肢体缺血				Lead Clinical-Stage Product Candidate 领先的临床期候选产品
ACP-01					
	PAD 外周血管疾病				
	Angina Pectoris 心绞痛				
	Ischemic & dilated Cardiomyopathy 缺血性和扩张性心肌病				
	Congestive Heart Disease 充血性心脏病				Safety Trials (completed) in Multiple Indications 多个适应症的安全试验（已完成）
	Acute Myocardial Infraction 急性心肌梗死				
	Ischemic Renal Disease 缺血性肾脏疾病				
	Vascular Dementia 血管性痴呆				
	Erectile Dysfunction 勃起功能障碍				
NCP-01					
	Stroke 中风				R&D 研发
	Spinal Cord Injury 脊髓损伤				
	Amyotrophic Lateral Sclerosis (ALS) 肌萎缩性侧索硬化症（ALS）				
BCP-01					
	Bone fractures 骨折				R&D 研发
	Skeletal breaks 骨骼断裂				
	Surgical procedures 外科手术				

THE TYPE OF STEM CELL MATTERS干细胞的类型很重要

How is it done?

如何做到？

What do you get as the ACP-01 autologous cellular medicine? 什么是ACP-01自体细胞药？

Synergetic Cell Population (SCP): A blood-borne cell population containing core multipotent cells surrounded by supportive cells.
协同细胞群（SCP）：由支持细胞包围的核心多能细胞组成的血源性细胞群。

Multipotent Cell Enrichment: Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll gradient. Cells were than subjected to a second density-based cell enrichment step using Percoll.
多能细胞富集：使用分离液梯度分离外周血单个核细胞（PBMCs）。然后使用细胞分离液进行第二次基于密度的细胞富集步骤。

Uniquely stable ACP-01 Product Characteristics and Product Stability!
独特的稳定的ACP-01产品特性和产品稳定性!

ACPs are stable for 35 hours (shelf-life) in syringes! ACPs
在注射器中稳定35小时（保质期）！



MULTIPLE NEAR-TERM CATALYSTS ANTICIPATED (2021-2022)多个近期预期催化剂（2021-2022年）

2021

APRIL 四月

Completion of Phase 2 Trial in CLI (last patient follow-up completed: ***April, 30, 2021*** 完成CLI的2期试验（最后一次病人随访完成时间：***2021年4月30日***）

MAY 五月

Emerging Growth Conference: ***May 26, 2021 (Virtual)*** 新兴增长会议：***2021年5月26日（虚拟）***

JUNE 六月

ASCENT Limb Preservation Conference: ***June 25-26, 2021 (Virtual)*** / ASCENT肢体保存会议：***2021年6月25-26日（虚拟）***。

JULY 七月

Sir Anthony Ritossa's 15th Global Family Office Investment Summit: ***June 30-July 1, 2021 (Monte Carlo, Monaco)*** 安东尼-里托萨爵士的第15届全球家庭办公室投资峰会：***2021年6月30日至7月1日（摩纳哥蒙特卡洛）***

AUGUST 八月

Amputation Prevention Symposium (AMP) Conference: ***August 11-14, 2021 (Virtual)*** 截肢预防研讨会（AMP）会：***2021年8月11-14日（虚拟）***

SEPTEMBER 九月

Symposium on Advanced Wound Care (SAWC) Conference: ***October 29-30, 2021 (Las Vegas, NV)*** 高级伤口护理研讨会（SAWC）会议：***2021年10月29-30日(内华达州拉斯维加斯)***

OCTOBER 十月

ARM’s Cell & Gene Meeting on the Mesa Conference: ***October 12-14, 2021 (Carlsbad, CA)*** Mesa会议上的ARM细胞和基因会议：***2021年10月12-14日（加利福尼亚州卡尔斯巴德）***

2022

JANUARY一月

International Symposia on Endovascular Therapy (ISET) Conference: ***January 16-19, 2022 (Hollywood, FL)*** 国际血管内治疗研讨会（ISET）会议：***2022年1月16-19日（佛罗里达州好莱坞）***

FEBURARY 二月

MARCH 三月

APRIL 四月

ARM’s Cell & Gene Meeting on the Mediterranean Conference: ***April 19-21, 2022*** 地中海会议上的ARM细胞与基因会议：***2022年4月19-21日***

MAY 五月

American Society of Gene & Cell Therapy Conference: ***May 16-19, 2022 (Washington, DC)*** 美国基因与细胞治疗学会会议：***2022年5月16-19日（华盛顿特区)***

HEMOSTEMIX

REALIZING THE IMPORTANCE OF INNOVATIVE CELLULAR MEDICINES认识到创新细胞药物的重要性

Disease Trends Support the Need for New Therapies 疾病趋势支持对新疗法的需求

CLI is a major global health problem - incidence growing with diabetes and aging population /CLI是一个主要的全球健康问题--发病率随着糖尿病和人口老龄化而增长

CLI has limited treatment options– significant amputations and high cost to society / CLI的治疗方案有限--截肢人数众多，社会成本高昂

Cardiovascular disease (“CVD”) is the number one cause of deaths in North America and worldwide causing approximately 1 in 3 deaths 心血管疾病（"CVD"）是北美和全世界的头号死因，大约每3人中就有1人死亡

Rising healthcare and economic costs- CVD costs anticipated to double by 2035 in USA 医疗保健和经济成本不断上升--预计到2035年，美国心血管疾病成本将翻倍

Strong Government and Public support 强大的政府和公众支持

Regenerative medicine is the leading edge for biotech investment 再生医学是生物技术投资的前沿领域

Unmet need for new less invasive, less expensive non-surgical treatments 对新的创伤小、成本低的非手术治疗的需求尚未得到满足

Right to try legislation approved in the USA mirrors EU and SE Asia autologous conventions of use 美国批准的尝试权立法反映了欧盟和东南亚的自体使用惯例

There is a gradual shift away from drugs toward personalized cell-based therapies 逐渐从药物转向基于细胞的个性化治疗方法

Population and Lifestyle Factors 人口和生活方式因素

Aging populations worldwide 全球人口老龄化

Good health and quality of life are key concerns with aging 良好的健康和生活质量是老龄化面临的关键问题

Poor diet and lifestyle increase prevalence of conditions of ischemia - related diseases treatable with ACP-01. 不良饮食习惯和生活方式增加了缺血状况的发生率--相关疾病可通过ACP-01进行治疗。

ENGINEERED ACP-01 工程化的ACP-01
KEY DIFFERENTIATORS 关键差异化因素

Autologous. Proven **safety and efficacy** 自体的。经证实的**安全性和有效性**。

Blood draw: **safer, less invasive** than fat or bone marrow 抽血：**比脂肪或骨髓更安全，创伤更小**。

Global portfolio of **91 patents** 全球**91项专利**组合
Including automated production 包括自动化生产

Non-surgical, enhanced cell therapy treatment for restoring circulation to blood starved tissues and organs
非手术、增强型细胞疗法治疗，用来恢复缺血组织和器官的血液循环

Low Patient Risks 患者风险低

Self-donation, means no immune rejection or disease transmission **自体捐赠**，意味着没有免疫排斥或疾病传播

High Cell Viability 高细胞活力

Fresh cells in ready-to-use syringes, **no cryopreservation** required **新鲜细胞保存**在即用型注射器中，**不需要低温保存**

Simple Protocol方案简单

Safe and easy to perform in outpatient clinic **能在门诊中安全和容易地**执行。

No Ethical Concerns 没有伦理问题

Stem cells derived directly from patient **干细胞**直接来自病人

No Reported Safety Issues 没有报告的安全问题

No mobilization drugs needed to collect cells 不需要收集细胞**的动员剂**

Scalable可扩展

Simple, cost-effective production process **简单、经济的**生产过程

ENGINEERED ACP-01 工程化的ACP-01

COMMERCIAL OPPORTUNITY AND UPSIDE MARKET POTENTIAL 商业机会和上升的市场潜力

Critical Limb Ischemia
Peripheral Arterial Disease
严重肢体缺血周边动脉疾病

Angina and CVD 心绞痛和心血管疾病

Ischemic Renal Disease 缺血性肾脏疾病

Vascular Dementia 血管性痴呆

Ischemic Erectile Dysfunction Disease
缺血性勃起功能障碍疾病

CLI - Tip of the Iceberg CLI--冰山一角

CLI - Estimated total costs up to

$248B[1] in US.

CLI--估计在美国的总支出高达**$2480亿[1]**。

Cardiovascular Disease 心血管疾病

In the United States, total costs of CVD in 2016 was **$555B; it is projected to be $1.1T** by 2035 在美国，2016年心血管疾病的总成本为**$5550亿；预计到2035年将达到$1.1万亿。**

[1]Source 来源: The Sage Group

[2]Source: American Heart Association Report: Cardiovascular Disease: A costly Burden for America 来源：美国心脏协会报告：心血管疾病：美国昂贵的负担

HEMOSTEMIX

WHY ACP-01 FOR CLI? 为什么将ACP-01用于CLI?
IT SAVES LIMBS 它可以拯救四肢

Hope for CLI Patients Facing Amputation 是面临截肢的CLI患者的希望



1

Extract and enrich patient's own cell population from peripheral blood 从外周血中提取并丰富患者自身的细胞群

2

Inject patient's cell population to form new blood vessels, saving limb 注射病人的细胞群以形成新的血管，拯救肢体

SELF-DONOR 自体捐赠
Uses patient's own cells, no immune rejection, no observed safety issues 使用患者自身的细胞，没有免疫排斥反应，没有观察到安全问题

SIMPLE 简单
Cell harvest via blood draw 通过抽血收获细胞

QUICK 快捷
7 days from draw to reinjection into patient's limb 从抽血到重新注射到患者肢体用时7天

CLI WITH ACP-01
IMPROVEMENTS VISUALIZED使用ACP-01的CLI可视化改善

47 Days post ACP-01 Treatment
ACP-01治疗后47天

Before注射前





After治疗后





PHASE 2 TRIAL FOR
FOR CLI UPDATE 针对CLI更新第二期试验

Randomized, placebo-controlled double blind Phase 2 clinical trial to confirm the safety and efficacy of ACP-01 随机、安慰剂对照的双盲2期临床试验，以确认ACP-01的安全性和有效性。

US FDA and Health Canada approved trial protocol 美国FDA和加拿大卫生部批准了试验方案

Phase 2 Trial 第二期试验

CRO	**17 sites on-boarded 已有17个试验点入组**	**65th Patient enrolled 第65名患者入组**	**Multicenter in US and Canada 美国和加拿大多中心**	**FDA and Health Canada approved / FDA和加拿大卫生部批准**	**All follow-ups completed by Apr 所有随访在4月前完成**

ACP-01
PROCESS 过程

1. Blood collection and shipping 采血和运输
2. Isolation of SCP 分离单细胞蛋白质(SCP)
3. Culturing and differentiation of cells 细胞的培养和分化
4. Cell harvesting 细胞采收
5. Quality Control release tests and batch qualification 质量控制释放测试和批次鉴定
6. Packaging and shipping 包装和运输
7. Administration of cells to damaged tissue 给受损组织注射细胞

PHASE 2 第二期
CLI TRIAL MILESTONES / CLI试验里程碑



A catalyst for future trials 未来试验的催化剂

Progression of the CLI Trial has opened the door for other ACP-01 clinical trials /CLI试验的进展为其他ACP-01临床试验打开了大门

[1]Health Canada Phase 2 Trial continuation approval received in December 2017. 2017年12月获得加拿大卫生署2期试验的继续批准。
[2]US FDA Phase 2 Clinical Trial continuation approval received April 2018.; IND originally approved in August 2015. 2018年4月获得美国FDA第二期临床试验继续批准；最初于2015年8月批准新药临床试验。
[3]First patient treatment under continued clinical trial announced May 3. 2018. 2018年5月3日公布了第一例持续临床试验患者治疗。
[4]Anticipated timeline.: April 2021 Report See Forward-Looking Information. 预期时间线：2021年4月报告见前瞻性信息。

ACP-01 CLINICAL EXPERIENCE / ACP-01临床试验
TRIAL HISTORY 试验历史

TYPE OF STUDY 研究类型	Pilot Safety/ Feasibility 安全性/可行性试验	Phase 1b Safety and Efficacy 第1b期安全性和疗效	**Phase 2 Safety and Efficacy 第2期安全性和有效性**	Clinical Trial Safety/ Feasibility临床试验安全性/可行性	Safety and Efficacy 安全性和有效性	Safety and Efficacy 安全性和有效性
STUDY LOCATION 研究地点	Thailand泰国	Hungary 匈牙利	**Canada and United States 加拿大和美国**	Thailand泰国	Thailand泰国	Bangkok Heart Hospital 曼谷心脏病医院
STUDY DESIGN 研究设计	Open label 开放式标签	Open label 开放式标签	**Randomized Double Blind Placebo Controlled随机双盲安慰剂对照**	Open label 开放式标签	Open label 开放式标签	Open label 开放式标签
NUMBER OF SUBJECTS 受试者人数	6	20	**65** Analyses 分析	24 Planned (17 completed) 计划（17人完成）	106	41
PATIENTS 患者	Diagnosed CLI 诊断为CLI	Diagnosed PAD 诊断为PAD	**Diagnosed CLI 诊断为CLI**	Diagnosed Angina 诊断为心绞痛	Diagnosis of severe ischemic heart disease with continued angina pain or heart failure symptoms 伴有持续心绞痛或心力衰竭症状的严重缺血性心脏病的诊断	Diagnosed Ischemic Cardiomyopathy or Dilated Cardiomyopathy诊断为缺血性心肌病或扩张型心肌病
STUDY STATUS 研究状态	Completed 已完成	Completed And Published已完成并且出版	**In Progress. Enrollment suspended during Midpoint Analysis 正在进行中。中点分析期间暂停招募**	Completed And Published 已完成并且出版	Completed 已完成 Results Available 有结果	Completed And Published 已完成并且出版

HEMOSTEMIX
EXPERIENCED SENIOR LEADERSHIP TEAM 经验丰富的高级领导团队

Management and Directors 管理层和董事

Peter Lacey, ICD.D 董事协会董事

Chairman of the Board 董事会主席

Dr. Ronnie Hershman, M.D., F.C.C.S. 博士、医学博士、F.C.C.S.

Director 董事

Loran Swanberg

Director 董事

Thomas Smeenk, BA文学学士

President, CEO, Co-Founder & Director / 总裁、首席执行官、联合创始人兼董事

Christina Wu, CPA, CGA注册会计师、CGA

Interim Chief Financial Officer 临时首席财务官

Advisory Board 咨询委员会

Timothy Chang, BA 文学学士

Private Investor and an investment committee member of an Asian-based hedge fund with average total AUM of approximately US$1 billion

私人投资者和亚洲对冲基金的投资委员会成员，平均资产管理总额约10亿美元

David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir.

First Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet Minister Served as the Minister of Consumer and Commercial Relations, Solicitor General, Chair of Management Board and Minister of Culture 第一个被选入加拿大任何省级立法机构并被任命为内阁部长的日裔加拿大人，任消费者和商业关系部长、副检察长、管理委员会主席和文化部长。

Honorable Shelia Copps, OC, PC 尊敬的Shelia Copps, OC, PC

Former Deputy Prime Minister of Canada, Minister of Environment, Minister of Heritage and a senior member of the federal cabinet for 10 years 曾任加拿大副总理、环境部长、遗产部长和联邦内阁高级成员达10年之久

CERVUS EQUIPMENT · LANDSMAN · NYU Langone Health · Swanberg AIR INC. · Vieworx · Torex Gold RESOURCES INC. · BROADWAY GOLD MINING · marrelli Group of Companies · RSM

HEMOSTEMIX
EXPERIENCED SENIOR LEADERSHIP TEAM 经验丰富的高级领导团队

Scientific Advisory Board
科学顾问委员会

Dr. York Hsiang, MB, ChB, MHSc, FRCSC 博士

Professor of Vascular Surgery at University of British Columbia, and Consultant Surgeon at the Vancouver General Hospital

卑诗大学血管外科教授，温哥华综合医院外科顾问

Dr. Pierre Leimgruber, MD, FACC 博士、医学博士

Board-certified in internal medicine, cardiovascular diseases, and interventional cardiology. Specialist in cardiovascular disease treatment

获得内科、心血管疾病和介入性心脏病学的董事认证。 心血管疾病治疗专家。

Dr. Alan B. Lumsden, M.D.博士， 医学博士

Walter W. Fondren III Chair, Medical Director of the Houston Methodist DeBakey Heart and Vascular Center and chair of the Department of Cardiovascular Surgery at Houston Methodist Hospital since 2008

Walter W. Fondren III主席，休斯顿卫理公会DeBakey心脏和血管中心的医疗主任，自2008年起担任休斯顿卫理公会医院心血管外科的主席。

Dr. Norman C. W. Wong, B.Sc (Hon), M.Sc, M.D., FRCP(C) 博士、理学学士 (荣誉)、 理学硕士、医学博士

Co-Founder of Resverlogix Corp. (TSX:RVX), and Chief Scientific Officer since 2003

Resverlogix Corp.(TSX:RVX)的共同创始人并从2003年起担任首席科学官。

Dr. Kumar L. Hari, PhD 博士

Chief Scientific Officer at cBio, a private disease diagnostics and tracking firm Kumar

是私人疾病诊断和跟踪公司cBio的首席科学官

Abbott
Lilly
MERCK FROSST
Découvrir toujours plus. Vivre toujours mieux.
gsk GlaxoSmithKline
SOLVAY PHARMACEUTICALS
Myelin Repair Foundation
Collaboration. Acceleration. Results.
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE CIRM
RESVERLOGIX

SHARE CAPITAL
OVERVIEW 股本概述

Share capital structure as of March 23, 2021 ($CAD)
截至2021年3月23日的股本结构（加元）

	Number 数量	Ex. Price 行使价	Expiry or Closing 到期或截止日期
Common Shares Issued and Outstanding 已发行普通股	56,197,154		
Stock Options 股票期权	5,342,000	$0.70-$2.00	Apr 2023-Dec 2025 / 2023年4月-2025年12月
Share Purchase Warrants[2] 认股权证[2] Finder Warrants (See note 1 below) 中间人认股权证（见下文注释1）	39,241,349 2,395,548	$0.55 - $1.00 $0.20-$1.00	Mar 2021-Dec 2021 / 2021年3月-2021年12月 Mar 2021-Dec 2021 / 2021年3月-2021年12月
Fully Diluted[1] (Includes dilutive effect of 2 x finder warrants) 完全摊薄[1]（包括2倍中间人认股权证的摊薄影响）	103,176,050[1]		

[1]Includes 1,197,774 finder warrants which are exercisable into Units (one share and one warrant; totaling 1,197,774 shares and 1,197,774 warrants). [1]包括1,197,774份可行使为单位（1股和1份认股权证；共计1,197,774股和1,197,774份认股权证）的中间人认股权证。

[2]Share Purchase Warrants – (each warrant exercisable into a share) [2]认股权证-（每份认股权证可行使为一股股份）

Number数量	Ex. Price 行使价	Expiry 到期时间
13,618,522	$0-55 - $1.00	Mar 5-Mar 25, 2021 / 2021年3月5日-3月25日
9,177,125	$1.00	May 7-July 9, 2021 / 2021年5月7日-7月9日
918,450	$1.00	Nov 24, 2021 / 2021年11月24日
15,527,251	$1.00	Dec 18-Dec 25, 2021 / 2021年12月18日至12月25日

HEMOSTEMIX TODAY 现在的HEMOSTEMIX

CLINICAL-STAGE COMPANY PIONEERING “BEST-IN-CLASS” ENGINEERED STEM CELLS 处于临床期的公司，开创了"同类最佳"的工程干细胞

“Organs Under Construction”, *Newsweek* Magazine Special Edition– Your Health in the 21st Century, *June 2005*

“Biotech, Finally.” BusinessWeek Magazine. *June 13, 2005.*

Time USA edition featuers VesCell *December 03, 2005*

Time Magazine Features VesCell Adult Stem Cell Therapy *November 20, 2005*

The Nation, Thai Daily Newspaper *July 28, 2005*

PROCEEDINGS AND DEBATES OF THE 109th CONGRESS *July 17, 2006*

Newsweek

BusinessWeek

THE NATION — INSIGHTFUL, IN TREND, INDEPENDENT

TIME

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

FRONTIERS IN MEDICINE

Stem Cells in the Treatment of Disease

Helen M. Blau, Ph.D., and George Q. Daley, M.D., Ph.D.

HEMOSTEMIX

RIGHTS OF ACTION FOR DAMAGES OR RESCISSION要求损害赔偿或撤销的诉讼权利

The following statutory rights of action for damages or rescission will only apply to a purchaser of securities of the Company in the event that this presentation is deemed to be an offering memorandum pursuant to applicable securities legislation in certain provinces of Canada. These remedies, or notice with respect thereto, must be exercised, or delivered, as the case may be, by the purchaser within the time limits prescribed by the applicable provisions of the provincial securities legislation. Purchasers should refer to the applicable securities legislation for the complete text of these rights or consult with a legal adviser. Where used in this section, "Misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made.

Ontario

Securities legislation in Ontario provides that purchasers of securities are entitled to rights of action for rescission or damages where an offering memorandum and any amendment to it contains a Misrepresentation. In accordance with Section 130.1 of the Securities Act (Ontario) (the "Ontario Act"), in the event that an offering memorandum or any amendment thereto contains a Misrepresentation, a purchaser who purchases securities offered by such offering memorandum during the period of distribution has, without regard to whether the purchaser relied upon the Misrepresentation, a right of action against the issuer for damages, or, while still the owner of the such securities purchased by that purchaser, for rescission, in which case, if the purchaser elects to exercise the right of rescission, the purchaser will have no right of action for damages against the issuer, provided that: (a) the issuer will not be liable if it proves that the purchaser purchased the securities with knowledge of the Misrepresentation; (b) in the case of an action for damages, the issuer will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the Misrepresentation relied upon; and (c) in no case will the amount recoverable in any action exceed the price at which the securities were sold to the purchaser.

A purchaser resident in Ontario should refer to the provisions of the Ontario Act and its regulations for particulars of the rights and defences discussed above and consult with a lawyer. The rights discussed above are in addition to and without derogation from any other right or remedy which a purchaser might have at law.

No action shall be commenced to enforce these statutory rights more than: (a) in an action for rescission, 180 days from the date of the transaction that gave rise to the cause of action; or (b) in an action for damages, the earlier of: (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action; or (ii) three years after the date of the transaction that gave rise to the cause of action.